AZD1775 Induces Toxicity Through Double-Stranded DNA Breaks Independently of Chemotherapeutic Agents in p53-Mutated Colorectal Cancer Cells by Webster, PJ et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=kccy20
Download by: [University of Leeds] Date: 04 January 2018, At: 07:55
Cell Cycle
ISSN: 1538-4101 (Print) 1551-4005 (Online) Journal homepage: http://www.tandfonline.com/loi/kccy20
AZD1775 induces toxicity through double-stranded
DNA breaks independently of chemotherapeutic
agents in p53-mutated colorectal cancer cells
Peter John Webster, Anna Tiffany Littlejohns, Hannah Jane Gaunt, K. Raj
Prasad, David John Beech & Dermot Anthony Burke
To cite this article: Peter John Webster, Anna Tiffany Littlejohns, Hannah Jane Gaunt, K. Raj
Prasad, David John Beech & Dermot Anthony Burke (2017) AZD1775 induces toxicity through
double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal
cancer cells, Cell Cycle, 16:22, 2176-2182, DOI: 10.1080/15384101.2017.1301329
To link to this article:  https://doi.org/10.1080/15384101.2017.1301329
© 2017 Peter John Webster, Anna Tiffany
Littlejohns, Hannah Jane Gaunt, K. Raj
Prasad, David John Beech, and Dermot
Anthony Burke. Published with license by
Taylor & Francis.
View supplementary material 
Accepted author version posted online: 15
Mar 2017.
Published online: 09 Nov 2017.
Submit your article to this journal 
Article views: 354 View related articles 
View Crossmark data
REPORT
AZD1775 induces toxicity through double-stranded DNA breaks independently
of chemotherapeutic agents in p53-mutated colorectal cancer cells
Peter John Webstera, Anna Tiffany Littlejohns a, Hannah Jane Gaunta, K. Raj Prasadb, David John Beecha,
and Dermot Anthony Burkea,c
aSchool of Medicine, University of Leeds, Leeds, UK; bDepartment of Hepatobiliary and Transplant Surgery, St. James’s University Hospital, Leeds, UK;
cDepartment of Colorectal Surgery, St. James’s University Hospital, Leeds, UK
ARTICLE HISTORY
Received 29 November 2016
Revised 29 January 2017
Accepted 24 February 2017
ABSTRACT
AZD1775 is a small molecule WEE1 inhibitor used in combination with DNA-damaging agents to cause
premature mitosis and cell death in p53-mutated cancer cells. Here we sought to determine the
mechanism of action of AZD1775 in combination with chemotherapeutic agents in light of recent ﬁndings
that AZD1775 can cause double-stranded DNA (DS-DNA) breaks. AZD1775 signiﬁcantly improved the
cytotoxicity of 5-FU in a p53-mutated colorectal cancer cell line (HT29 cells), decreasing the IC50 from
9.3 mM to 3.5 mM. Flow cytometry showed a signiﬁcant increase in the mitotic marker pHH3 (3.4% vs.
56.2%) and DS-DNA break marker gH2AX (5.1% vs. 50.7%) for combination therapy compared with 5-FU
alone. Combination therapy also increased the amount of caspase-3 dependent apoptosis compared with
5-FU alone (4% vs. 13%). The addition of exogenous nucleosides to combination therapy signiﬁcantly
rescued the increased DS-DNA breaks and caspase-3 dependent apoptosis almost to the levels of 5-FU
monotherapy. In conclusion, AZD1775 enhances 5-FU cytotoxicity through increased DS-DNA breaks, not
premature mitosis, in p53-mutated colorectal cancer cells. This ﬁnding is important for designers of future
clinical trials when considering the optimal timing and duration of AZD1775 treatment.
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Introduction
Colorectal cancer is a global health problem with 693,900 deaths
occurring annually worldwide.1 Conventional medical therapies
for colorectal cancer, such as chemotherapy and radiotherapy,
cause cell death by inducing lethal DNA damage in cancer cells.
In health, DNA damage activates cell cycle checkpoints (G1,
S- and G2/M) that arrest the cell cycle allowing DNA to be
repaired. If the damage is too severe pathways that lead to cell
death are activated, otherwise DNA damage will be accurately
repaired. Understandably this is an essential process in healthy
cells to preserve genomic integrity, but in cancerous cells this
can limit the efﬁcacy of DNA-damaging treatments.
WEE1 is a protein kinase that regulates cell entry into mitosis
at the G2/M checkpoint through the activity of cyclin-dependent
kinase 1 (CDK1). In response to DNA damage, WEE1 inacti-
vates CDK1 through an inhibitory phosphorylation of its tyro-
sine 15 residue (pCDK1-Y15).2 This results in G2 arrest and
allows DNA damage to be repaired. The combination of WEE1
inhibitors with DNA-damaging agents has emerged as an attrac-
tive anti-cancer treatment strategy, whereby cancer cells with
lethal DNA damage are forced into premature mitosis with
unrepaired DNA damage, resulting in cell death. This is thought
to be particularly effective in cancers with non-functioning p53
(a key component of the G1 checkpoint) as these cells are more
reliant on the G2/M checkpoint for DNA repair. Preclinical
studies in several cancer lines, including colorectal cancer,
support this theory.3-6 Currently there are over 25 clinical trials
assessing AZD1775 (a small molecule WEE1 inhibitor) in com-
bination with DNA-damaging agents in a range of cancers
(Clinical Trails.gov Accessed August 2016).
Interestingly, several studies have demonstrated that AZD1775
has anti-cancer activity independent of p53 function.7-11 In 2012 it
was reported that WEE1, through CDK1, has another critical role
in DNA synthesis.12 WEE1 inhibition results in increased activity
of CDK1, which in turn leads to increased replication origin ﬁring,
exhaustion of nucleotide stores, reduced replication fork speed
and double-stranded DNA (DS-DNA) breaks. This has been sup-
ported by several pre-clinical studies showing single agent
AZD1775 activity.7,9,13 The ﬁrst Phase I clinical trial for AZD1775
monotherapy in solid tumors has also recently been reported.14
Whether or not AZD1775 increases the sensitivity of
p53-mutated and wild type cancer cells to DNA-damaging
therapies and the mechanism by which it achieves this sensiti-
zation are unanswered questions.15 To address this we investi-
gated the mechanism of action of AZD1775 in combination
with chemotherapeutic agents in a p53-mutated colorectal
cancer cell line.
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Results
AZD1775 enhances 5-FU toxicity in HT29 cells, but does
not enhance toxicity of other common chemotherapeutic
agents
In the majority of current clinical trials AZD1775 is adminis-
tered following DNA-damaging treatment to cause mitotic
catastrophe and cancer cell death. We sought to understand
how this dosing strategy affected p53-mutated HT29 colorec-
tal cancer cell viability with different chemotherapeutic
agents commonly used for the treatment of colorectal cancer.
5-FU alone caused about a 30% reduction in HT29 cell
viability (Fig. 1a) as did 300 nM AZD1775 (Fig. S1). Combi-
nation treatment showed an enhancing effect of AZD1775 at
low doses of 5-FU, slightly increased maximum response to
5-FU and reduction in the 5-FU IC50 from 9.3 mM
to 3.5 mM (Fig. 1b). When used in combination with
oxaliplatin, AZD1775 decreased cell viability at low doses of
oxaliplatin, but not higher doses (Fig. 1c). The IC50 was
signiﬁcantly higher with combination treatment than
oxaliplatin alone (Fig. 1d). Similarly, with irinotecan and
AZD1775 combination therapy, cell viability was decreased
at lower doses of irinotecan but not higher doses (Fig. 1e).
There was no signiﬁcant difference in the IC50 values
Figure 1. AZD1775 Enhances the Cytotoxicity of 5-FU, but not Oxaliplatin or Irinotecan. (a-f). Measurements of cell viability in HT29 cells using WST-1. (a) Concentration-
response data for HT29 cells treated for 24 hrs with 5-FU at the indicated doses and then an additional 24 hrs with AZD1775 (300 nM) or vehicle control (n D 3, N D 9).
(b) Mean data derived from the ﬁtted Hill Equation in a indicating the 50% maximum inhibition (IC50) values (nD 3). (c) As for a but substituting 5-FU for varying concen-
trations of oxaliplatin (nD 3, ND 9). (d) Mean IC50 values from the type of experiment shown in c (nD 3). (e) As for a but replacing 5-FU with irinotecan (nD 3, ND 9). (f)
Mean IC50 values from the type of experiment shown in e (nD 3).
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(Fig. 1f). Overall, the data suggest that 5-FU cytotoxicity is
improved with AZD1775 addition, but both oxaliplatin
and irinotecan treatments are only improved at low concen-
trations. It is unclear whether the effect of AZD1775 is addi-
tive or synergistic.
AZD1775 increases S phase and G2/M phase populations
in HT29 cells pre-treated with 5-FU
To further investigate the mechanism by which AZD1775
addition enhances chemotherapy cytotoxicity, we focused on
concentrations of 1 mM 5-FU and 300 nM AZD1775 as this
resulted in a 31% reduction in HT29 viability compared with
1 mM 5-FU alone (Fig. 1a). Treatment with 5-FU signiﬁ-
cantly increased pCDK1-Y15 indicating mitotic delay in
response to DNA damage (Fig. 2a and b). With AZD1775
addition, pCDK1-Y15 was signiﬁcantly reduced as WEE1
was prevented from phosphorylating CDK1 (Fig. 2a and b).
As WEE1, through CDK1, regulates entry into mitosis we
investigated the effect of combination treatment on the cell
cycle distribution. The addition of AZD1775 grossly altered
the cell cycle pattern (Fig. 2c). As expected, there were more
cells in S Phase and G2/M phase (Fig. 2d). This reﬂects the
dual role of CDK1 as a regulator of DNA synthesis and
mitotic entry. The data suggest that AZD1775 alters CDK1
activity and is able to increase the number of 5-FU treated
HT29 cells in S Phase and G2/M Phase.
AZD1775 causes increased mitosis and DS-DNA breaks in
HT29 cells pre-treated with 5-FU
Both premature mitosis and DS-DNA breaks have been
reported to be responsible for AZD1775 cytotoxicity. To inves-
tigate how AZD1775 was working in combination with 5-FU
we produced a ﬂow cytometry time course assessing levels of
DS-DNA breaks and mitosis after AZD1775 addition (Fig. 3a
and b). With combination therapy levels of DS-DNA breaks
increased over time to 50.7% 24 hrs after AZD1775 addition,
compared with 5.1% in 5-FU alone (Fig. 3c). In contrast, levels
of mitosis peaked 8 hrs after AZD1775 addition at 56.2% com-
pared with 3.4% in 5-FU alone. Levels of mitosis almost
returned to baseline at 24 hrs (Fig. 3d). Similar effects were
observed with AZD1775 monotherapy (Fig. S2). The data sug-
gest that AZD1775 can induce both mitosis and DS-DNA
breaks in cells pre-treated with 5-FU.
DS-DNA breaks caused by combination therapy can be
reversed by exogenous nucleoside addition
As AZD1775 monotherapy causes DS-DNA breaks in HT29
cells (Fig. S2) it was hypothesized that this may also be the
dominant mechanism of action for combination therapy. Criti-
cal to investigating this was the fact that nucleotide shortage is
a consequence of excess origin ﬁring and not premature mito-
sis. AZD1775 monotherapy resulted in 45.2% of HT29 cells
Figure 2. AZD1775 Decreases pCKD1-Y15 in 5-FU Treated HT29 Cells and Increases the Number of Cells in S Phase and G2/M Phase. (a) Example western blot labeled with
anti-pCDK1-Y15, anti-CDK1 and anti-b-actin antibodies for HT29 cells that received no treatment (Untreated), AZD1775 (300 nM), 5-FU (1 mM) or 5-FU (1 mM) with an
additional 24 hrs AZD1775 (300 nM). (b) Quantiﬁcation of the pCDK1-Y15 band intensity divided by the CDK1 band intensity. Data has been normalized to the untreated
group (n D 3 each). (c) Example ﬂow cytometry recording for HT29 cells that received no treatment (Untreated), AZD1775 (300 nM), 5-FU (1 mM) or 5-FU (1 mM) with an
additional 24 hrs AZD1775 (300 nM). The vertical dotted lines separate different phases of the cell cycle. (d) Mean percentage of cells in G0/G1, S- and G2/M phases (n D
3 each). 5-FUCAZD1775 data are statistically compared with 5-FU for each phase.
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expressing gH2AX, a 452-fold increase compared with vehicle
control treated cells (Fig. 4a and b). The addition of exogenous
nucleosides signiﬁcantly reduced gH2AX expression to 4%
(Fig. 4a and b). When AZD1775 was used in combination with
5-FU a similar result was noted. The addition of exogenous
nucleosides to 5-FU and AZD1775 combination therapy signif-
icantly reduced the number of cells expressing gH2AX from
50.5% to 8.7% (Fig. 4c and d). This was near the levels of 5-FU
alone (4.5%). Similar results were observed in the HCT116
colorectal cancer cell line, which have wild type p53 status,
although higher doses of AZD1775 were required to observe an
effect (Fig. S3). Overall, the data suggest that DS-DNA breaks
induced by 5-FU and AZD1775 combination therapy occur
independently of p53 status and can be prevented if there is an
exogenous supply of nucleosides.
AZD1775 increases caspase-3 dependent apoptosis in
HT29 cells pre-treated with 5-FU and can be reversed by
exogenous nucleoside addition
A possible consequence of DS-DNA breaks is increased apo-
ptotic cell death. Therefore, we investigated the levels of cas-
pase-3 dependent apoptosis following combination therapy. 5-
FU alone resulted in low levels of apoptosis (4%), however this
was signiﬁcantly increased with combination therapy up to
13% (Fig. 5a and b). To address whether this observation was
due to increased DS-DNA breaks as a result of WEE1 inhibi-
tion we added exogenous nucleosides. This reduced the amount
of caspase-3 dependent apoptosis to 4.7%, which was similar to
levels observed with 5-FU treatment alone (Fig. 5a and b). The
data suggest that combination therapy results in increased apo-
ptotic cell death, but this is due to AZD1775 causing DS-DNA
breaks, not premature mitosis.
Discussion
This study shows that when AZD1775 is used in combination
with 5-FU against a p53-mutated colorectal cancer cell line the
enhanced cytotoxicity is due to AZD1775 causing increased
DS-DNA breaks, not premature mitosis. AZD1775 exerts its
own cytotoxic effects independent of chemotherapeutic agents.
There is disparity within the literature regarding the domi-
nant mechanism of action of AZD1775, especially when used
in combination with DNA-damaging agents.15 Furthermore, it
is unclear what role p53 status has upon AZD1775 efﬁcacy. To
address this we took advantage of the HT29 colorectal cancer
cell line as this has a mutated non-functional p53 (Arg-273 to
His) and therefore both DS-DNA breaks and premature mito-
sis are possible mechanisms of AZD1775 action. Our ﬁndings
contradict previous studies in colorectal cancer cell lines that
Figure 3. 5-FU and AZD1775 Combination Therapy Causes Increased Mitosis and DS-DNA Breaks in HT29 Cells. (a) Example ﬂow cytometry dot plots for unlabelled HT29
cells (red) and HT29 cells labeled with anti-gH2AX antibody (blue) after 24 hrs treatment with 5-FU (1 mM) and the addition of AZD1775 (300 nM) for the times indicated.
(b) Example ﬂow cytometry dot plots for unlabelled HT29 cells (blue) and HT29 cells labeled with anti-pHH3 antibody (purple) after 24 hrs treatment with 5-FU (1 mM)
and the addition of AZD1775 (300 nM) for the times indicated. (c) Mean gH2AX expression for the groups in a including a control group (5-FU) where cells were treated
for 24 hrs with 5-FU (1 mM) and vehicle control for the times indicated (n D 3 each time point). (d) Mean pHH3 expression for the groups in b including a control group
(5-FU) where cells were treated for 24 hrs with 5-FU (1 mM) and vehicle control for the times indicated (n D 3 each time point).
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suggest WEE1 inhibition sensitizes cells to DNA-damaging
agents through premature mitosis.3-5 However, these studies
were published before the role of WEE1 in regulating DNA
synthesis was discovered and so DS-DNA breaks were not
investigated. As we have shown, levels of mitosis do dramati-
cally increase, but this is not the cause of caspase-3 dependent
apoptosis. Furthermore, our results are in agreement with
several reports of single agent AZD1775 activity causing DS-
DNA breaks in cancer cells.9,13,14
Despite acting independently of chemotherapeutic agents,
AZD1775 did improve the IC50 of 5-FU in viability assays.
However, this is probably due to 5-FU monotherapy having
limited effects on HT29 cells, even at high doses. AZD1775 has
potent monotherapeutic action against HT29 cells and has
Figure 4. DS-DNA Breaks Caused by AZD1775 and 5-FU Combination Therapy can be Prevented by Exogenous Nuceloside Addition. (a) Four example ﬂow cytometry dot
plots for unlabelled HT29 cells (red) and HT29 cells labeled with anti-gH2AX antibody (blue). Cells were treated for 24 hrs with vehicle control (Control), exogenous
nucleosides (Nuc, EmbryoMax, 1:5 dilution), AZD1775 (300 nM) or AZD1775 (300 nM) C exogenous nucleosides (Nuc, EmbryoMax, 1:5 dilution). (b) Mean gH2AX
expression for the 4 groups in a (n D 3 each). (c) Four example ﬂow cytometry dot plots for unlabelled HT29 cells (red) and HT29 cells labeled with anti-gH2AX antibody
(blue). All cells received 24 hrs 5-FU (1 mM) followed by either vehicle control, exogenous nucleosides (Nuc, EmbryoMax, 1:5 dilution), AZD1775 (300 nM) or AZD1775
(300 nM) C exogenous nucleosides (Nuc, EmbryoMax, 1:5 dilution) for a further 24 hrs. (d) Mean gH2AX expression for the 4 groups in c (n D 3 each).
Figure 5. AZD1775 and 5-FU Combination Therapy Induce Caspase-3 Dependent Apoptosis, which can be Prevented by Exogenous Nucleoside Addition. (a) Images of
ﬂuorescence from caspase-3 activity indicator in HT29 cells. All cells received 24 hrs 5-FU (1 mM) followed by 24 hrs of either vehicle control, exogenous nucleosides
(Nuc, EmbryoMax , 1:5 dilution), AZD1775 (300 nM) or AZD1775 (300 nM) C exogenous nucleosides (Nuc, EmbryoMax, 1:5 dilution). Scale bars 200 mm. (b) Mean data
for the experimental groups in a (n D 3 each).
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been found to have more potent effects on cell viability than
some DNA-damaging agents in other cancer cell lines.16 We
demonstrated that AZD1775 monotherapy is able to inhibit
HT29 cell proliferation with an IC50 of 184 nM (Fig. S1). This
was signiﬁcantly less than the IC50 for 5-FU, which was 9.3 mM
and therefore using an AZD1775 dose of 300 nM is likely to
result in independent cytotoxic effects. If AZD1775 is used in
conjunction with chemotherapeutic agents clinically, it may
mean that lower doses of chemotherapy can be given to
patients. This could have the beneﬁt of reducing the side effects
associated with high dose chemotherapy, while maintaining the
same efﬁcacy.
This ﬁnding has clinical relevance as AZD1775 is currently
being investigated in several clinical trials in combination with
DNA-damaging treatments. As our data suggest that AZD1775
causes DS-DNA breaks rather than premature mitosis, giving
AZD1775 immediately after DNA-damaging treatments of
short periods may not be the optimal dosing strategy. Instead,
longer term treatments with AZD1775 in conjunction with
DNA-damaging agents may have better efﬁcacy.
In conclusion, the data suggest that AZD1775 has indepen-
dent cytotoxic effects from chemotherapeutic agents in p53-
mutated colorectal cancer cells. This ﬁnding is important for
designers of future clinical trials when considering the timing
and duration of AZD1775 treatment.
Materials and methods
Cell culture and reagents
HT29 cells (ATCC HTB-38TM) were purchased from Sigma.
This cell line was established in 1964 from the primary tumor
of a 44-year-old Caucasian female with colorectal adenocarci-
noma. These cells have a mutated p53 (Arg-273 to His).
HCT116 cells were also purchased from Sigma. Both cell lines
were cultured in Dulbecco’s Modiﬁed Eagle Medium Gluta-
tMAX (Invitrogen) supplemented with 10% foetal calf serum
and 100 units.mL¡1 penicillin-streptomycin. 5-FU, oxaliplatin
and irinotecan were purchased from Sigma. Nucleosides
(EmbryoMax 100x) were purchased from Millipore and
AZD1775 was purchased from Active Biochem.
WST-1 proliferation assay
WST-1 is a colorimetric assay used for the non-radioactive
quantiﬁcation of cell proliferation, viability and cytotoxicity.
Cells were plated onto a 96-well plate and grown overnight.
The following morning cells were treated with chemotherapeu-
tic agents for 24 hrs, before the addition of AZD1775. Upon
completion of the experiment WST-1 (Sigma) was applied in
accordance with the manufacturer’s protocol and absorbance
was measured in a microtiter plate reader at wavelengths
between 440 and 650 nm.
Western blotting
Cells were harvested in lysis buffer containing 10 mM Tris, pH
7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40, MiniComplete
protease inhibitors (Roche), and PhosSTOP phosphatase
inhibitors (Roche). Equal protein amounts were loaded on 4–
20% gradient gels and resolved by electrophoresis. Samples
were transferred to PVDF membranes and labeled overnight
with primary antibody: mouse anti-human b-actin (1:2000,
Santa Cruz Biotechnology), rabbit anti-human pCDK1-Y15
(1:1000, Cell Signaling Technology), mouse anti-human CDK1
(1:1000, Cell Signaling Technology). Species appropriate sec-
ondary antibodies and SuperSignal Femto detection reagent
(Perbio Science) were used for visualization.
Flow cytometry
All ﬂow cytometry work was undertaken on a BD-LSR Fortessa
Flow Cytometer. HT29 cells were plated at 325,000 cells per
well on a 6-well plate and grown overnight before treatment.
At the end of treatment cells were trypsinised and spun down.
Ice-cold ethanol (70%) was added dropwise to each pellet
before samples were frozen at ¡20C for at least 48 hrs. To
detect DS-DNA breaks, samples were defrosted, washed twice
with PBS and then incubated with Alexa Fluor 488 Mouse anti-
H2AX (BD Biosciences) for 20 mins at room temperature. Fol-
lowing incubation samples were washed again with PBS before
adding 0.5 mL per 1 £ 106 cells PI/RNase Buffer (BD Bioscien-
ces). Samples were incubated at room temperature for 15 mins
before being analyzed on the ﬂow cytometer. To detect mitosis
cells were incubated with Alexa Fluor 647 Rat anti-pHH3 (BD
Biosciences), with other steps remaining unchanged. All analy-
sis was undertaken using BD FACSDiva v6.2 software.
Apoptosis assay
HT29 apoptosis was measured using a caspase-3 assay on the
IncucyteTM FLR Kinetic Imaging System. HT29 cells were
plated onto a 6-well plate and grown overnight before treat-
ment. Following treatment cells were incubated with 5 mM
NucViewTM488 caspase-3 substrate (Biotium) according to
manufacturer’s instructions. Cells were placed in the
IncucyteTM FLR and imaged in phase contrast and ﬂuorescence
mode using a x10 objective to detect apoptotic cells. To detect
the total cell population cell nuclei were then stained with
5 mM Vybrant DyeCycle Green (Molecular Probes, Invitro-
gen). Apoptotic Index was calculated as the percentage of cas-
pase-3 positive cells divided by the total number of cells.
Data analysis
Statistical Analysis was performed using OriginPro 9.1 (Origin-
Lab Corporation). Data are presented as mean C/- SEM. Prior
to statistical analysis, data were tested for normality and equal-
ity of variance. Paired data were compared statistically using t
tests. For data sets with more than 2 groups ANOVA and a
post-hoc Bonferroni test were used. “n” indicates the number
of independent experiments, where as “N” indicates the num-
ber of replicates. For statistical signiﬁcance  indicates p < 0.05,
 p < 0.01 and p < 0.001. NS D Not signiﬁcant.
Disclosure of potential conﬂicts of interest
No potential conﬂicts of interest were disclosed.
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